Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 2,071 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Memorial Sloan Kettering Cancer Center Clear all
Completed Phase 2 Interventional Results available

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

NCT00200161
View directory record Official record
Conditions
Glioblastoma, Gliomas
Interventions
Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy

NCT00017056
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
ixabepilone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

NCT03082677
View directory record Official record
Conditions
Myeloid Hematologic Malignancy, Lymphoid Hematologic Malignancy
Interventions
Ixazomib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 16, 2026, 8:51 AM EDT
Recruiting Phase 2 Interventional

Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

NCT07218601
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Breath sample collection, Research blood collection
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas

NCT00004057
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
L-778,123, paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 16, 2026, 8:51 AM EDT
Terminated Phase 2 Interventional Results available

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

NCT00988169
View directory record Official record
Conditions
Lung Cancer
Interventions
oral erlotinib and pulsed doses of oral AT-101
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00004012
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
capecitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

NCT01908777
View directory record Official record
Conditions
T Cell Non-Hodgkin Lymphoma
Interventions
High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
10
States / cities
Tampa, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer

NCT00002466
View directory record Official record
Conditions
Kidney Cancer, Sarcoma
Interventions
cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 16, 2026, 8:51 AM EDT
Active, not recruiting Phase 1 Interventional

MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

NCT04555551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Infusion of MCARH109 T cells
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 16, 2026, 8:51 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

NCT04381988
View directory record Official record
Conditions
COVID-19, Cancer
Interventions
Hydroxychloroquine, Placebo, Radiation therapy
Drug · Other · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Study of gp75 Vaccine in Patients With Stage III and IV Melanoma

NCT00034554
View directory record Official record
Conditions
Malignant Melanoma
Interventions
gp75 DNA vaccine
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2010 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

NCT00003105
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 16, 2026, 8:51 AM EDT
Recruiting Not applicable Interventional

A Study of Music Therapy for Anxiety in People With Cancer

NCT07845422
View directory record Official record
Conditions
Cancer
Interventions
AI-Assisted Collaborative Songwriting (ARTIST) Intervention, Time and attention matched-music listening (TAME)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Fluorescent Imaging of Nerves With Illuminare-1 During Surgery

NCT04983862
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Illuminare-1, Karl Storz D-Light C photodynamic diagnostic (PDD)
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

NCT00739141
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome, Non-Hodgkins Lymphoma, Chronic Myelogenous Leukemia, Hodgkins Lymphoma
Interventions
fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 16, 2026, 8:51 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

NCT03414229
View directory record Official record
Conditions
Sarcoma
Interventions
Epacadostat, Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Not applicable Interventional

Randomized Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection

NCT01058746
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
restrictive perioperative fluid management, Liberal perioperative fluid management
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

NCT00470366
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
pegfilgrastim, cisplatin, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 16, 2026, 8:51 AM EDT
Active, not recruiting Phase 1 Interventional

Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity

NCT00393783
View directory record Official record
Conditions
Breast Cancer
Interventions
MAB HER 2 (HERCEPTIN)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 16, 2026, 8:51 AM EDT
Completed No phase listed Observational

Sensory Morbidity Following Breast Surgery

NCT00625924
View directory record Official record
Conditions
Breast Cancer
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Oct 16, 2026, 8:51 AM EDT
Completed No phase listed Observational

Breast MRI Spectroscopy, Department of Defense (DOD)

NCT00582569
View directory record Official record
Conditions
Breast Lesion
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 16, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

NCT00940524
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
Dasatinib, Mitoxantrone, Cytarabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 16, 2026, 8:51 AM EDT
Recruiting Phase 2 Interventional

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

NCT02974647
View directory record Official record
Conditions
Lymphoma
Interventions
Ruxolitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
10
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 16, 2026, 8:51 AM EDT